1. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study.
- Author
-
Volker Mall, Florian Heinen, Andrea Siebel, Christoph Bertram, Ulrich Hafkemeyer, Jörg Wissel, Steffen Berweck, Fritz Haverkamp, Günter Nass, Leo Döderlein, Nico Breitbach-Faller, Wilhelm Schulte-Mattler, and Rudolf Korinthenberg
- Subjects
SPASTICITY ,CEREBRAL palsy ,BRAIN damage ,DEVELOPMENTAL disabilities ,BOTULINUM toxin - Abstract
Adductor spasticity in children with cerebral palsy (CP) impairs motor function and development. In a placebo-controlled, double-blind, randomized multicentre study, we evaluated the effects of botulinum toxin A(BTX-A) in 61 children (37 males, 24 females; mean age 6 years 1 month [SD 3y 1mo]) with CP (leg-dominated tetraparesis, n=39; tetraparesis, n=22; GMFCS level I, n=3; II, n=6; III, n=17; IV, n=29; V, n=6). Four weeks after treatment, a significant superiority of BTX-A was observed in the primary outcome measure (knee–knee distance ‘fast catch’, p=0.002), the Ashworth scale (p=0.001), and the Goal Attainment Scale (p=0.037). [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF